

CCI Penalises GSK and Sanofi ₹60 Crore, ₹3 Cr

Our Bureau

New Delhi: The Competition Commission of India (CCI) has imposed a ₹60 crore penalty on GlaxosmithKline and ₹3 crore on Sanofi India for indulging in unfair trade practices. CCI has given both pharmaceutical majors 60 days to deposit the amount.

Acting on a complaint of a UP-based vaccine maker Bio-Med, CCI found both companies



CCI found both cos formed a cartel to secure govt tenders for meningitis vaccine

had formed a cartel to secure government tenders for the supply of meningitis vaccine meant for Haj-bound pilgrims. The complainant also alleged unilateral government action in introducing and modifying the turnover conditions for the tender without any reasonable rationale and explanation. "It was alleged that the government kept increasing eligibility criteria (turnover wise) every year from 2008 to 2012 for

facilitating the cartel between Glaxosmith-Kline and Sanofi," a senior CCI official said.

"It was found that upon disqualification of the informant in 2012 due to modifications of eligibility conditions, both companies colluded to divide the entire tendered quantities and to earn super normal profits by quoting significantly higher prices," the CCI order said.

GOW